Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Mineros reported strong sales of 61.8Koz AuEq in Q2, displaying 13% YoY growth, and modestly beating our forecast.</li>
<li>MSA continues to execute on growth at both assets, which includes plant optimizations at Hemco and improvement initiatives at Nechí.</li>
<li>Stronger sales were driven by Hemco, where 37.2Koz Au (+12% YoY) beat our 33.7Koz, and silver sales over doubled YoY.</li>
</ul>


Mineros reported strong sales of 61.8Koz AuEq in Q2, displaying 13% YoY growth, and modestly beating our forecast.
MSA continues to execute on growth at both assets, which includes plant optimizations at Hemco and improvement initiatives at Nechí.
Stronger sales were driven by Hemco, where 37.2Koz Au (+12% YoY) beat our 33.7Koz, and silver sales over doubled YoY.


MSA: Q2 Displays Ongoing Growth; Guidance Revised Higher on Hemco

Mineros SA

MSA: Q2 Displays Ongoing Growth; Guidance Revised Higher on Hemco